Hjem › Makuladegeneration › Florida › Orlando
Makuladegeneration kliniske forsøg i Orlando, FL
5 studier for Makuladegeneration søger deltagere på steder i og omkring Orlando (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
RekruttererFase 2/3
- Florida Eye Clinic (Site 130), Altamonte Springs · 9 mi væk
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RekruttererFase 3
- Florida Retina Institute - Orlando, Orlando
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RekruttererFase 2
- Florida Retina Institute, Orlando
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
RekruttererFase 2/3
- Florida Retina Institute, Orlando
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RekruttererFase 3
- Florida Retina Institute, Orlando
Makuladegeneration forsøg i andre byer
- Dallas, TX13 studier
- Erie, PA10 studier
- The Woodlands, TX9 studier
- Sacramento, CA8 studier
- Reno, NV8 studier
- Hagerstown, MD8 studier
- Phoenix, AZ7 studier
- Cleveland, OH7 studier
- Houston, TX7 studier
- Salt Lake City, UT7 studier
- Boston, MA7 studier
- Austin, TX7 studier
Andre studier i Orlando
- Ikke-småcellet lungecancer44 studier
- Overvægt31 studier
- Metastatisk cancer29 studier
- Overvægt27 studier
- Alzheimers sygdom25 studier
- Type 2-diabetes24 studier
- Kræft (alle typer)24 studier
- Brystkræft23 studier
- Ægstockræft22 studier
- Ulcerøs colitis22 studier
- Lungecancer21 studier
- Colorektal kræft19 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.